Indaptus Therapeutics, Inc. (INDP)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jeffrey A. Meckler J.D. | CEO & Director | 937.8k | -- | 1967 |
| Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer & Director | -- | -- | 1956 |
| Mr. Walt Addison Linscott Esq. | Chief Operating Officer | 788.24k | -- | 1961 |
| Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer | 746.72k | -- | 1967 |
| Mr. Nir Sassi | CFO, Secretary & Treasurer | 378.47k | -- | 1976 |
Indaptus Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 7
Description
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Corporate Governance
Upcoming Events
May 14, 2025 at 12:00 PM UTC
Indaptus Therapeutics, Inc. Earnings Date
Recent Events
March 13, 2025 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
February 13, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
February 11, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission